Rivals Explore Booming Weight-Loss Drug Market Entry
Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade.
Stay updated with breaking news from Bryan Crowe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade.
The Anglo-Swedish drugmaker last month placed a $2 billion bet by licensing an experimental pill from China's Eccogene that it believes could cause fewer side effects than current injectable weight-loss treatments. AstraZeneca was "a few years behind" the runaway success of Novo and Lilly's drugs and was "working on the next wave of products", CEO Pascal Soriot told Reuters last month. The company is focusing on overweight population with risk factors like hypertension and kidney disease as opposed to a cosmetic market.
(Reuters) - Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by...
(Reuters) - Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by...
15.11.2023 - TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Piper Sandler 35th Annual Healthcare Conference at 8:30 a.m. ET on Tuesday, November 28, 2023 ...